Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
Data from Beaujon University provide new insights into colon cancer
July 9th, 2009
According to a study from Clichy, France, "Acquired resistance to protein kinase C (PKC) modulators may explain the failure of clinical trials in patients with cancer. Herein, we established a human colon cancer cell line resistant to PEP005, a drug that inhibits PKC alpha and activates PKC delta." "Colo205-R cells, selected by stepwise exposure to PEP005, were > 300-fold more resistant to PEP005 than parental Colo205-S cells and were cross-resistant to phorbol 12-myristate 13-acetate, bryostatin, bistratene A, and staurosporine. No PKC alpha or PKC delta mutation was detected in Colo205-S and Colo205-R cells. Changes in Colo205-R cells were reminiscent of the...
Source: Gene Therapy Weekly (2009-07-09)
|
